Grassroots campaign to promote Rx drug risk awareness

Share this article:
A grassroots coalition of healthcare advocates gearing up to launch a campaign intent on creating awareness about the risks and benefits of prescription drugs. The effort, dubbed “Just Say Know to Prescription Drugs,” will launch on Oct. 7, at a press conference in Washington, DC, and be followed by an online push to have one million patients download a form to bring to their prescribing physicians to evaluate the drugs they are recommended. Using the provided form, patients will be able to collect risk/benefit information and require a physicians’ signature attesting the patient has been fully informed of side effects and non-drug alternatives. “We are interested in people being informed about being better patients and being able to give informed consent,” said Domminick Riggio, psychologist and executive director of the International Center for the Study of Psychiatry and Psychology, a group participating in the campaign. “We feel that most consumers don’t get the opportunity to make this risk/reward decision.” Riggio added that, most of the time, doctors are getting slanted information from sales reps instead of “real research.” Calls to pharmaceutical industry trade group PhRMA requesting comment for this story went unreturned at press time.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...